The science is moving fast and in the right direction. More and more, we are seeing transformative treatments that address severe conditions, achieve R&D and regulatory milestones. For some of these diseases, a cure is no longer a mere aspiration. It is now a reality. Recent advances in cell and gene therapies have played a prominent role in this healthcare renaissance. While this trend certainly represents a great hope for patients, their families and healthcare professionals – the costs are likely to put payers’ and insurers’ finances under pressure. In addition to financial considerations, other aspects such as value of cure, allocation/prioritization of healthcare investments, decreased burden of disease and new payment approaches are at the very center of policy discussions and likely to produce profound changes in the way these technologies are assessed, priced and reimbursed. Cell and gene therapies are at the core of the consulting offer that forethought access would be pleased to share with prospective customers.